Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 92

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 92
---
 forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus.
See “Where You Can Find More Information.”

<div align='center'>58

USE OF PROCEEDS</div>

We expect to receive approximately
$9.1 million in net proceeds from the sale of Ordinary Shares offered by us in this offering (approximately $10.6 million
if the Representative’s exercises its over-allotment option in full), based upon an assumed public offering price of $11.00 per
Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us.

Each $0.25 increase or
decrease in the assumed initial public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set
forth on the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $0.23 million, assuming
the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of
Ordinary Shares we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares offered by us would increase
(decrease) the net proceeds to us from this offering by $1.01 million, assuming no change in the assumed initial public offering
price and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million                                                                                                    
 for development activities (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million                                      
 for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million               
 for research and development activities; |

| ● | approximately $0.5 million                                                          
 for EU marketing development (